Treatment of Gastroesophageal Junction Carcinoma

Ian Chau, MD, of Royal Marsden Hospital in London, reviews first- and second-line treatment options for patients with carcinoma of the gastroesophageal junction. In the first-line setting, different standards for treatment duration exist around the world, including the idea of relinking with the same chemotherapy if a patient achieves stable disease. In the second-line setting, Chau discusses the use of chemotherapy and ramucirumab.